Alder BioPharmaceuticals (ALDR) Tops Q4 EPS by 1c

Alder BioPharmaceuticals (NASDAQ: ALDR) reported Q4 EPS of $0.22, $0.01 better than the analyst estimate of $0.21. Revenue for the quarter came in at $6.4 million versus the consensus estimate of $5.7 million.

For earnings history and earnings-related data on Alder BioPharmaceuticals (ALDR) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Terreno Realty Corp (TRNO) PT Raised to $75 at KeyBanc on 'Improving Demand'
• Freedom Broker Upgrades Willis Lease Finance Corp. (WLFC) to Buy